OPCML, a novel systems regulator of tyrosine kinase signaling in ovarian and other cancers

od Gabra, H
Wydane 2012

Continuous 5-fluorouracil in the treatment of breast cancer.

od Cameron, D. A., Gabra, H., Leonard, R. C.
Wydane 1994

Frozen-section examination in the management of paediatric testicular lesions

od O’Connor, E., Roy, C., Annavarapu, S., Gabra, H. O.
Wydane w Pediatr Surg Int (2021)

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer

od Alifrangis, C, Thornton, A, Fotopoulou, C, Krell, J, Gabra, H
Wydane w Gynecol Oncol Rep (2016)

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

od Sharma, R, Graham, J, Mitchell, H, Brooks, A, Blagden, S, Gabra, H
Wydane 2009

High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.

od Devlin, J., Elder, P. A., Gabra, H., Steel, C. M., Knowles, M. A.
Wydane 1996

Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.

od Gabra, H., Cameron, D. A., Lee, L. E., Mackay, J., Leonard, R. C.
Wydane 1996

A prognostic model for ovarian cancer

od Clark, T G, Stewart, M E, Altman, D G, Gabra, H, Smyth, J F
Wydane 2001

Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours.

od Gabra, H., Taylor, L., Cohen, B. B., Lessels, A., Eccles, D. M., Leonard, R. C., Smyth, J. F., Steel, C. M.
Wydane 1995

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

od Vasey, P A, Gore, M, Wilson, R, Rustin, G, Gabra, H, Guastalla, J-P, Lauraine, E P, Paul, J, Carty, K, Kaye, S
Wydane 2008

WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear

od GOURLEY, C., PAIGE, A.J.W., TAYLOR, K.J., SCOTT, D., FRANCIS, N.-J., RUSH, R., ALDAZ, C.M., SMYTH, J.F., GABRA, H.
Wydane 2005

Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer

od Harding, V, Fenu, E, Medani, H, Shaboodien, R, Ngan, S, Li, H K, Burt, R, Diamantis, N, Tuthill, M, Blagden, S, Gabra, H, Urch, C E, Moser, S, Agarwal, R
Wydane 2012

Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes

od Stemke-Hale, Katherine, Shipman, Kristy, Kitsou-Mylona, Isidora, de Castro, David Gonzalez, Hird, Vicky, Brown, Robert, Flanagan, James, Hani Gabra, H, Mills, Gordon B., Agarwal, R, El-Bahrawy, Mona
Wydane 2012

LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression

od Mura, M, Hopkins, T G, Michael, T, Abd-Latip, N, Weir, J, Aboagye, E, Mauri, F, Jameson, C, Sturge, J, Gabra, H, Bushell, M, Willis, A E, Curry, E, Blagden, S P
Wydane w Oncogene (2015)

Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus

od Tomlinson, V A L, Newbery, H J, Bergmann, J H, Boyd, J, Scott, D, Wray, N R, Sellar, G C, Gabra, H, Graham, A, Williams, A R W, Abbott, C M
Wydane 2007

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCO...

od Banerjee, S., Rustin, G., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., Gilby, E., Hogg, M., Harper, P., Kipps, E., Lewsley, L-A, Hall, M., Vasey, P., Kaye, S. B.
Wydane w Ann Oncol (2012)

High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group.

od Cameron, D. A., Craig, J., Gabra, H., Lee, L., MacKay, J., Parker, A. C., Leonard, R. C., Anderson, E., Anderson, T., Chetty, U., Dixon, M., Hawkins, A., Jack, W., Kunkler, I., Leonard, R., Matheson, L., Miller, W.
Wydane 1996

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, p...

od Glasspool, R M, Brown, R, Gore, M E, Rustin, G J S, McNeish, I A, Wilson, R H, Pledge, S, Paul, J, Mackean, M, Hall, G D, Gabra, H, Halford, S E R, Walker, J, Appleton, K, Ullah, R, Kaye, S
Wydane 2014

Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer

od Matassa, D S, Amoroso, M R, Lu, H, Avolio, R, Arzeni, D, Procaccini, C, Faicchia, D, Maddalena, F, Simeon, V, Agliarulo, I, Zanini, E, Mazzoccoli, C, Recchi, C, Stronach, E, Marone, G, Gabra, H, Matarese, G, Landriscina, M, Esposito, F
Wydane w Cell Death Differ (2016)

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium

od Goranova, T, Ennis, D, Piskorz, A M, Macintyre, G, Lewsley, L A, Stobo, J, Wilson, C, Kay, D, Glasspool, R M, Lockley, M, Brockbank, E, Montes, A, Walther, A, Sundar, S, Edmondson, R, Hall, G D, Clamp, A, Gourley, C, Hall, M, Fotopoulou, C, Gabra, H, Freeman, S, Moore, L, Jimenez-Linan, M, Paul, J, Brenton, J D, McNeish, I A
Wydane w Br J Cancer (2017)